Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Incyte
Biotech
Lilly’s $2.3B Ajax drug works ‘right out of the gate’
The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu
Jun 13, 2026 11:15am
Incyte inks $2B deal to add Star biz to late-phase constellation
Jun 8, 2026 9:07am
Incyte pays Genesis $80M to expand AI-fueled drug discovery pact
May 20, 2026 10:22am
Incyte inks deal with Edison to train AI through drug discovery
May 19, 2026 10:30am
Incyte’s vitiligo bet scores ph. 3 wins but can’t shake off Rinvoq
Apr 28, 2026 9:52am
Tang takes over Aurinia after FDA brouhaha—Chutes & Ladders
Mar 27, 2026 11:05am
